Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 5.3% – Should You Sell?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price fell 5.3% during mid-day trading on Tuesday . The company traded as low as $11.05 and last traded at $11.17. 69,312 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 326,035 shares. The stock had previously closed at $11.79.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on YMAB shares. Wedbush reaffirmed an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. BMO Capital Markets lowered their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, August 13th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday, November 15th. Finally, Morgan Stanley reduced their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $21.38.

Y-mAbs Therapeutics Stock Performance

The business has a 50 day simple moving average of $13.43 and a 200 day simple moving average of $12.81.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. During the same period in the previous year, the business posted ($0.18) EPS. Sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the sale, the insider now owns 67,681 shares of the company’s stock, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp increased its holdings in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Caligan Partners LP increased its stake in Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after acquiring an additional 613,175 shares during the last quarter. Geode Capital Management LLC grew its stake in Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after buying an additional 47,846 shares during the period. Dimensional Fund Advisors LP boosted its position in Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Millennium Management LLC grew its stake in shares of Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after buying an additional 67,233 shares in the last quarter. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.